BoneSupport company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


About BoneSupport

BoneSupport specializes in injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT|G is the first CE-marked injectable gentamicin antibiotic eluting ceramic bone graft substitute. CERAMENT|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries.

BoneSupport Headquarter Location

Scheelevagen 19A

Lund, SE-223 70,


+46 46 286 53 70

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BoneSupport

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BoneSupport is included in 3 Expert Collections, including Advanced Materials.


Advanced Materials

1,253 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.


Medical Devices

11,588 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Latest BoneSupport News

14:35 EDT MCRA Assists BONESUPPORT AB with the First Ever Combination Product DeNovo Decision Granted by the U.S. FDA

Jun 16, 2022

News provided by Share this article CERAMENT G is the first combination product which has successfully navigated the DeNovo process. To date, MCRA has supported 5 of the 9 orthopedic DeNovos granted by the U.S.FDA, including the first 3 orthopedic and spine DeNovos. WASHINGTON, June 16, 2022 /PRNewswire/ -- MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization (CRO) integrating U.S. and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, Quality Assurance, and Cybersecurity is pleased to announce its role in the granting of the DeNovo by the U.S. Food and Drug Administration (FDA) for BONESUPPORT'S  CERAMENT G, an implantable device/drug combination bone void filler that provides a one-stage approach for the management of bone infection with its unique dual mode of action that delivers proven bone remodeling with reliable and safe local elution of gentamicin to protect bone healing. BONESUPPORT's CERAMENT G is the first antibiotic-eluting bone void filler to gain FDA approval. The DeNovo was supported by extensive laboratory testing, animal studies, and a robust clinical study of CERAMENT G which demonstrated a low recurrence of osteomyelitis and proven bone remodeling. Emil Billback, Chief Executive Officer at BONESUPPORT said, "We've worked with MCRA since 2016. MCRA's integrated service divisions have been very helpful and supportive in providing valuable strategic guidance and project support to BONESUPPORT since that time. I have been extremely happy with our decision to work with MCRA in support of our regulatory needs which is evidenced by this DeNovo achievement. We also appreciate the integrated role of the statistical experts from Biomedical Statistical Consulting in performing the analyses of our clinical data." Hollace Rhodes, MCRA's Vice President of Orthopedic Regulatory Affairs, said, "We were pleased to work with BONESUPPORT's team to bring this Breakthrough technology to the U.S. market. For the first time, patients in the U.S. will have access to CERAMENT G and its one-stage solution to osteomyelitis." MCRA is at the forefront of helping companies navigate the DeNovo regulatory pathway to achieve success in bringing novel devices to the U.S. market. To date, MCRA's clinical and regulatory teams have supported 5 of the 9 orthopedic DeNovos granted by the U.S. FDA, including the first 3 orthopedic and spine DeNovos. About MCRA, LLC: MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm. MCRA delivers to its clients industry experience at integrating five business value creators: regulatory, clinical research, reimbursement, healthcare compliance, and quality assurance to provide a dynamic, market-leading effort from innovation conception  to commercialization. MCRA's integrated application of these key value-creating initiatives provides unparalleled value for its clients. MCRA has offices in Washington, DC, Hartford, CT, and New York, NY, and served nearly 1,000 clients globally. Its core focus areas of therapeutic experience include orthopedics, spine, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, general surgery, digital health, neurology, robotics, and in vitro diagnostic (IVD) devices and medical device cybersecurity. About Viscogliosi Brothers, LLC: Viscogliosi Brothers, LLC (VB), founded MCRA in 2004. VB is headquartered in New York City and specializes in funding venture capital, private equity, and merchant banking activities for the neuromusculoskeletal industry. VB is dedicated to financing healthcare innovation.   About BONESUPPORT AB: BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden.    For more information, please contact: Elizabeth Baldacchino

BoneSupport Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BoneSupport Rank

  • When was BoneSupport founded?

    BoneSupport was founded in 1999.

  • Where is BoneSupport's headquarters?

    BoneSupport's headquarters is located at Scheelevagen 19A, Lund.

  • What is BoneSupport's latest funding round?

    BoneSupport's latest funding round is IPO.

  • How much did BoneSupport raise?

    BoneSupport raised a total of $79.98M.

  • Who are the investors of BoneSupport?

    Investors of BoneSupport include HealthCap Venture Capital, Industrifonden, Lundbeckfond Ventures, Tellacq, AP3 and 9 more.

  • Who are BoneSupport's competitors?

    Competitors of BoneSupport include RxSight, Cagenix, BAROnova, SpineForm, Gentis and 11 more.

You May Also Like


SpineForm is developing a less invasive spinal deformity surgical treatment. SpineForm's HemiBridge is a spinal implant designed to help correct and straighten spinal deformities in growing children, without the need for a brace or extensive future spinal fusion surgeries.

Minimus Spine Logo
Minimus Spine

Minimus Spine is developing ozone injection technology specifically for spinal applications. The company has improved upon the existing technology through a system that creates ozone, and measures its concentration, within in a sterile, syringe-cartridge. This has advantages in terms of sterility and dose assurance, as well as material compatibility, which are vital to the advancement of this technique.


Kyphon develops and markets medical devices designed to restore spinal function using minimally invasive technologies. The company's KyphX(R) line of products is used in balloon kyphoplasty, a minimally invasive procedure to treat spinal fractures caused by osteoporosis or cancer. More information about the company can be found at

TransCorp Logo

TransCorp develops and commercializes minimally invasive surgical instruments and implants for neurosurgical and orthopedic applications.

Cross Trees Medical

Cross Trees Medical offers products for vertebral fracture treatment


Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine, which causes back pain. The company's first patented product, DiscCell, is a breakthrough injectable biomaterial that augments or replaces the diseased nucleus pulposus of the spinal disc.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.